IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
A Olar, KM Wani, KD Alfaro-Munoz, LE Heathcock… - Acta …, 2015 - Springer
Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation …
Introduction Isocitrate dehydrogenase (IDH) mutation status and grade define subgroups of
diffuse gliomas differing based on age, tumor location, presentation, and prognosis. While …
diffuse gliomas differing based on age, tumor location, presentation, and prognosis. While …
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification
G Berzero, AL Di Stefano, S Ronchi, F Bielle… - Neuro …, 2021 - academic.oup.com
Background Isocitrate dehydrogenase (IDH) wildtype (wt) grade II gliomas are a rare and
heterogeneous entity. Survival and prognostic factors are poorly defined. Methods We …
heterogeneous entity. Survival and prognostic factors are poorly defined. Methods We …
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis
P Metellus, B Coulibaly, C Colin, AM de Paula… - Acta …, 2010 - Springer
The phenotypic heterogeneity of low-grade gliomas (LGGs) is still inconsistently explained
by known molecular abnormalities in patients treated according to the present standards of …
by known molecular abnormalities in patients treated according to the present standards of …
[HTML][HTML] IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma
A Zeng, Q Hu, Y Liu, Z Wang, X Cui, R Li, W Yan… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract The current World Health Organization (WHO) classification of human gliomas is
mainly based on morphology. However, it has limitations in prognostic prediction. We …
mainly based on morphology. However, it has limitations in prognostic prediction. We …
MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis
JE Villanueva-Meyer, MD Wood… - American Journal of …, 2018 - Am Roentgen Ray Soc
OBJECTIVE. Grade II diffuse gliomas (DGs) with isocitrate dehydrogenase (IDH) mutations
are associated with better prognosis than their IDH wild-type counterparts. We sought to …
are associated with better prognosis than their IDH wild-type counterparts. We sought to …
[HTML][HTML] IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
HE Leeper, AA Caron, PA Decker, RB Jenkins… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Background Epigenetic, genetic, and molecular studies have identified several diagnostic
and prognostic markers in diffuse gliomas. Their importance for evaluating WHO grade II …
and prognostic markers in diffuse gliomas. Their importance for evaluating WHO grade II …
[HTML][HTML] Beyond IDH-mutation: emerging molecular diagnostic and prognostic features in adult diffuse gliomas
K Mirchia, TE Richardson - Cancers, 2020 - mdpi.com
Diffuse gliomas are among the most common adult central nervous system tumors with an
annual incidence of more than 16,000 cases in the United States. Until very recently, the …
annual incidence of more than 16,000 cases in the United States. Until very recently, the …
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
DE Reuss, Y Mamatjan, D Schrimpf, D Capper… - Acta …, 2015 - Springer
The WHO 2007 classification of tumors of the CNS distinguishes between diffuse
astrocytoma WHO grade II (A II WHO2007) and anaplastic astrocytoma WHO grade III (AA III …
astrocytoma WHO grade II (A II WHO2007) and anaplastic astrocytoma WHO grade III (AA III …
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis
H Sun, L Yin, S Li, S Han, G Song, N Liu… - Journal of Neuro-oncology, 2013 - Springer
Mutations in the gene encoding isocitrate dehydrogenase (IDH) have been identified in
approximately 65− 90% of low-grade gliomas (LGGs). Various studies examining the …
approximately 65− 90% of low-grade gliomas (LGGs). Various studies examining the …